IP Library › Granted Patent US 12,529,036
Granted Patent B2
US 12,529,036 · App. 17/050,946 · Granted Jan 20, 2026

Synthetic chimeric vaccinia virus

Inventors: David Evans (Edmonton, CA); Ryan Noyce (Edmonton, CA); Seth Lederman (Austin, TX)
Assignee: TONIX PHARMA LIMITED
C12N7/00A61K35/768A61K39/285A61K2039/525C12N2710/24132C12N2710/24134C12N2710/24143C12N2710/24151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,529,036
App. No.
17/050,946
Granted
Jan 20, 2026
Kind
B2
Abstract

The invention relates in various aspects to a synthetic chimeric vaccinia virus or compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric vaccinia viruses. The synthetic chimeric vaccinia viruses are well suited, among others, as virus vaccines or to generate an oncolytic response and pharmaceutical formulations.

Claims (26)

1 . A synthetic chimeric vaccinia virus (scVACV) that is replicated and reactivated from DNA derived from chemically synthesized DNA, the genome of said scVACV comprising one or more modifications to eliminate one or more unique restriction sites or to add or repair one or more unique restriction sites relative to a wild type vaccinia virus genome, wherein the scVACV further comprises a left and a right terminal hairpin loop derived from chemically synthesized DNA, one or both of the terminal hairpin loops being heterologous relative to the wild type vaccinia virus genome, and wherein the one or both of the terminal hairpin loops comprise different tandem repeat regions or a different number thereof relative to the wild type form of the one or both of the terminal hairpin loops.

2 . The scVACV of claim 1 , wherein the one or more modifications to eliminate one or more unique restriction sites comprises eliminating one or more AarI restriction sites or one or more BsaI restriction sites.

3 . The scVACV of claim 1 , wherein the wild-type vaccinia virus genome is selected from the group of strains consisting of: Western Reserve, Clone 3, Tian Tan, Tian Tan clone TP5, Tian Tan clone TP3, NYCBH, NYCBH clone Acambis 2000, Wyeth, Copenhagen, Lister, Lister 107, Lister-LO, Lister GL-ONC1, Lister GL-ONC2, Lister GL-ONC3, Lister GL-ONC4, IHD-W, LC16m18, Lederle, Tashkent clone TKT3, Tashkent clone TKT4, USSR, Evans, Praha, L-IVP, V—VET1, LIVP 6.1.1, Ikeda, EM-63, Malbran, Duke, 3737, CV-1, Serro 2, CM-01, NYCBH Dryvax clone DPP13, NYCBH Dryvax clone DPP15, NYCBH Dryvax clone DPP20, NYCBH Dryvax clone DPP17, NYCBH Dryvax clone DPP21, VACV-IOC, Chorioallantois Vaccinia virus Ankara (CVA), Modified vaccinia Ankara (MVA), and MVA-BN.

4 . The scVACV of claim 1 , wherein the one or both of the terminal hairpin loops are independently selected from a slow form or a fast form of a terminal hairpin loop of the wild-type vaccinia virus.

5 . The scVACV of claim 4 , wherein:

(a) the slow form is independently selected from a group of nucleotide sequences that comprises a nucleotide sequence that is at least 85% identical to, that is at least 90% identical to, that is at least 95% identical to, and that consists of the nucleotide sequence of SEQ ID NO: 13 or SEQ ID NO: 19; and

(b) the fast form is independently selected from a group of nucleotide sequences that comprises a nucleotide sequence that is at least 85% identical to, that is at least 90% identical to, that is at least 95% identical to, and that consists of the nucleotide sequence of SEQ ID NO: 14 or SEQ ID NO: 20.

6 . The scVACV of claim 1 , wherein the scVACV is replicated and reactivated from DNA derived from overlapping chemically synthesized DNA fragments comprising one or more modifications relative to the wild type vaccinia virus genome.

7 . The scVACV of claim 1 , wherein the scVACV is reactivated using leporipoxvirus-catalyzed recombination and reactivation, and wherein the leporipoxvirus is selected from the group consisting of: Shope fibroma virus (SFV), hare fibroma virus, rabbit fibroma virus, squirrel fibroma virus, and myxoma virus.

8 . A method of producing a synthetic chimeric vaccinia virus (scVACV) that is replicated and reactivated from DNA derived from chemically synthesized DNA comprising the steps of:

(i) chemically synthesizing DNA fragments, the DNA fragments corresponding to the DNA that is replicated and reactivated and comprising one or more modifications to eliminate one or more unique restriction sites or to add or repair one or more unique restriction sites relative to a wild type vaccinia virus genome;

(ii) chemically synthesizing DNA corresponding to a left and a right terminal hairpin loop, one or both loops being heterologous relative to the wild type vaccinia virus genome and wherein one or both of the terminal hairpin loops comprise different tandem repeats regions, or a different number thereof, than a corresponding wild type terminal hairpin loop, and ligating the terminal hairpin loops derived from the chemically synthesized terminal hairpin loops to the corresponding left termini and right termini of the DNA fragments derived from the chemically synthesized DNA of step (i);

(iii) transfecting the ligated DNA fragments of step (ii) into helper virus-infected cells;

(iv) culturing said cells to produce a mixture of helper virus and scVACV particles in said cells; and

(v) plating the mixture on host cells specific to the scVACV to recover the scVACV.

9 . The method of claim 8 , wherein the helper virus is selected from the group consisting of: a leporipoxvirus, a fowlpox virus and a psoralen-inactivated helper virus.

10 . The method of claim 8 , wherein the helper virus-infected cells are BGMK cells.

11 . The method of claim 8 , wherein the DNA fragments comprise:

(i) nucleotide sequences that are at least 85% identical to the sequences of SEQ ID NOs: 1-9;

(ii) nucleotide sequences that are at least 90% identical to the sequences of SEQ ID NOs: 1-9;

(iii) nucleotide sequences that are at least 95% identical to the sequences of SEQ ID NOs: 1-9; or

(iv) nucleotide sequences that consist of the sequences of SEQ ID NOs: 1-9.

12 . A pharmaceutical composition comprising an scVACV of claim 1 and a pharmaceutically acceptable carrier.

13 . The pharmaceutical composition according to claim 12 , wherein the scVACV is inactivated by heat, UV, or formalin.

14 . A method of triggering or boosting an immune response or immunizing a human subject against vaccinia virus, variola virus, or monkeypox virus, comprising administering to a subject in need thereof the scVACV of claim 1 or a pharmaceutical composition comprising the scVACV and a pharmaceutically acceptable carrier.

15 . A method of treating a variola virus infection or cancer, comprising administering to a subject in need thereof the scVACV of claim 1 or a pharmaceutical composition comprising the scVACV and a pharmaceutically acceptable carrier.

Assignments (5)
NOVATION AGREEMENT Recorded Sep 25, 2024
From: TONIX PHARMA HOLDINGS LIMITED
To: TONIX PHARMA LIMITED
Reel/Frame 069504/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2022
From: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
To: TONIX PHARMA LIMITED
Reel/Frame 060350/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2022
From: EVANS, DAVID; NOYCE, RYAN
To: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Reel/Frame 060350/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2020
From: LEDERMAN, SETH
To: TONIX PHARMACEUTICALS HOLDING CORP.
Reel/Frame 054195/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2020
From: TONIX PHARMACEUTICALS HOLDING CORP.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 054195/0066 →
Continuity (2)
Provisional Application 62665973 · May 2, 2018
Related Publication 20210230560A1 · Jul 29, 2021
References Cited (138)
US 2787577A · Allisbaugh · 1957 [cited by applicant]
US 4683195A · Mullis · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4754065A · Levenson · 1988 [cited by applicant]
US 4800159A · Mullis · 1989 [cited by applicant]
US 6004777A · Tartaglia · 1999 [cited by applicant]
US 6723325B1 · Weltzin · 2004 [cited by applicant]
US 8795667B2 · Johnson et al. · 2014 [cited by applicant]
US 11345896B2 · Evans · 2022 [cited by applicant]
US 12365879B2 · Evans et al. · 2025 [cited by applicant]
US 20040014034A1 · Evans · 2004 [cited by examiner]
US 20090053244A1 · Chen et al. · 2009 [cited by applicant]
US 20130216566A1 · Anderson · 2013 [cited by applicant]
US 20160010064A1 · Qin et al. · 2016 [cited by applicant]
US 20180251736A1 · Evans · 2018 [cited by applicant]
US 20180326039A1 · Haruta · 2018 [cited by applicant]
US 20230002741A1 · Evans et al. · 2023 [cited by applicant]
CN 105121635A · 2015 [cited by applicant]
EP 3045181 · 2016 [cited by applicant]
WO WO2005028634 · 2005 [cited by applicant]
WO WO2005103259 · 2005 [cited by applicant]
WO 2006022215A1 · 2006 [cited by applicant]
WO WO2007093133 · 2007 [cited by applicant]
WO WO2012142529A2 · 2012 [cited by examiner]
WO WO2013038066 · 2013 [cited by applicant]
WO WO2014160475 · 2014 [cited by applicant]
WO WO2017027757 · 2017 [cited by applicant]
WO WO2018057755 · 2018 [cited by applicant]
WO WO2018085582 · 2018 [cited by applicant]
WO WO2019043282 · 2019 [cited by applicant]
WO WO2019213452 · 2019 [cited by applicant]
Domi et al., “Engineering of a vaccinia virus bacterial artificial chromosome in [cited by examiner]
Zhu et al., “The attenuation of vaccinia Tian Tan strain by removal of the viral M1L-K2L genes,” Journal of Virological Methods 144: 17-26 (Year: 2007). [cited by examiner]
Buller et al., “Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype,” Nature, 317:813-815 (1985). [cited by applicant]
Baxby, “The origins of vaccinia virus,” Journal of Infectious Disease, 136(3):453-455 (1977). [cited by applicant]
Hendrickson et al., “Orthopoxvirus genome evolution: the role of gene loss,” Viruses, 2:1933-1967 (2010). [cited by applicant]
Josiah et al., “Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma,”' Molecular Therapy, 18(2):377-385 (2010). [cited by applicant]
Tonix Pharmaceuticals Press Release “Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus Pre-Clinical Smallpox-Preventing Vaccine Candidate TNX-801 May Qualify… [cited by applicant]
Czub et al., “Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets,” Vaccine, 23(17-18):2273-2279 (2005). [cited by applicant]
Gomez et al., “The Poxvirus Vectors MVA and NYVAC as Gene Delivery Systems for Vaccination Against Infectious Diseases and Cancer,” Current Gene Therapy, 8(2):97-120 (2008). [cited by applicant]
Antoine et al., “The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses,” Virology, 244(2):365-396 (1998). [cited by applicant]
Chan et al., “Oncolytic Poxviruses,” Annual Review of Virology, 1:191-214 (2014). [cited by applicant]
Kerrigan et al., “Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas,” Cytotherapy, 19(4):445-457 (2017). [cited by applicant]
Du et al., “Vaccinia virus DNA replication: two hundred base pairs of telomeric sequence confer optimal replication efficiency on minichromosome templates,” PNAS, 93(1):9693-9698 (1996). [cited by applicant]
Chakrabarti et al., “Compact, synthetic, vaccinia virus early/late promoter for protein expression, ” BioTechniques, 23(6):1094-1097 (1997). [cited by applicant]
Di Pilato et al., “Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression,” Journal of General Virology, 96(8):2360-2371 (2015). [cited by applicant]
Earl et al., “Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus,” Journal of … [cited by applicant]
Esparza et al., “Investigations on the historical origin and evolution of the smallpox vaccine,” Gac Med Caracas, 128(Supl 1):S88-S97 (2020). [cited by applicant]
Falkner et al., “ [cited by applicant]
Gammon et al., “Vaccinia Virus-Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis,” Plos Pathogens, 6(7):e1000984, pp. 1-20, 2010. [cited by applicant]
Hartman et al., “SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts,” PLOS … [cited by applicant]
Himly et al., “The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses,” Virology, 248(2):295-304 (1998). [cited by applicant]
Jenner, “An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of The Cow Pox,” Springfield… [cited by applicant]
Kolb et al., “Improvements in the rabbit scarification method for the assay of smallpox vaccine,” Bulletin of the World Health Organization, 25(1):19-24 (1961). [cited by applicant]
Korber et al., “Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,” bioRxiv 2020.04.29.069054 (2020) (33 pages). [cited by applicant]
Kremer et al., “Vaccinia virus and poxvirology, Methods and Protocols,” Second Edition, vol. 890, Humana Press, Totowa, NJ, pp. 59-92 (2012) (339 pages). [cited by applicant]
Leon et al., “The EB66® cell line as a valuable cell substrate for MVA-based vaccines production,” Vaccine, 34(48):5878-5885 (2016). [cited by applicant]
Lohr et al., “New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation,” Vaccine, 27(36):4975-4982 (2009). [cited by applicant]
Pallesen et al., “Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen,” PNAS, 114(35):E7348-E7357 (2017). [cited by applicant]
Ralph et al., “2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness,” Journal of Infection in Developing Countries, 31:14(1):3-17 (2020). [cited by applicant]
Rice et al., “An efficient method for generating poxvirus recombinants in the absence of selection,” Viruses, 3(3): 217-232 (2011). [cited by applicant]
Roberts et al., “A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice, ” PLoS Pathogens, 3(1):e5.doi:10.1371 (2007). [cited by applicant]
Sadoff et al., “Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineInterim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine,” New England Journal of Medicine, 384(19):1824-1835 (2021). [cited by applicant]
Subbarao et al., “Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice,” Journal of Virology, 78(7):3572-357… [cited by applicant]
Yager et al., “Pathology of Domestic Animals,” The skin and appendages, K. V. F. Jubb, p. C. Kennedy, N. Palmer, 4th Edition, vol. 1., Academic Press, San Diego, CA, pp. 531-738 (1993) (787 pages) (4 Parts). [cited by applicant]
Alzhonova et al., “T cell inactivation by poxviral B22 family proteins increases viral virulence, ” PLOS, 10(5):e1004123 (2014) (19 pages). [cited by applicant]
Aragon et al., “Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968,” BMC Public Health 3:26 1-12 (2003). [cited by applicant]
Aragon et al., “The risks and benefits of pre-event smallpox vaccination: where you stand depends on where you sit,” Annals of Emergency Medicine, 42(5):681-684 (2003). [cited by applicant]
Artenstein et al., “A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults,” Vaccine, 23: 3301-3309 (2005). [cited by applicant]
Attwood, “Genomics. The Babel of bioinformatics,” Science, 290(5491):471-473 (2000). [cited by applicant]
Baker, et al., “Protein structure prediction and structural genomics,” Science, 294(5540):93-96 (2001). [cited by applicant]
Baroudy et al., “Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain,” Cell, 28(2):315-24 (1982). [cited by applicant]
Brickmann et al., “Re-assembly of nineteenth-century smallpox vaccine genomes reveals the contemporaneous use of horsepox and horsepox-related viruses in the USA,” Genome Biology, 21:286 (2020) (6 pages). [cited by applicant]
Child et al., “Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo,” Virology, 174:625-629 (1990). [cited by applicant]
Couko et al., “Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer,” Clinical Cancer Research, 5(6):1523-37 (1999). [cited by applicant]
Damaso, “Revisiting Jenner's mysteries, the role of the Beaugency lymph in the evolutionary path of ancient smallpox vaccines,” Lancet, S1473-3099(17)30445 (2017) (9 pages). [cited by applicant]
DiEuliis, et al., “A Holistic Assessment of the Risks and Benefits of the Synthesis of Horsepox Virus,” mSphere, 3(2)e00074-18 (2018)(8 pages). [cited by applicant]
Draganov, et al., “Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers,” Journal of Translational Medicine, 17(1):100 (2019). [cited by applicant]
FDA Briefing Document, “Vaccines and Related Biological Products Advisory Committee Meeting,” Sep. 19, 2012 (30 pages). [cited by applicant]
Frey et al. “Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults,” Vaccine 27:1637-1644 (2008). [cited by applicant]
Frey et al., “Clinical responses to undiluted and diluted smallpox vaccine,” New England Journal of Medicine, 346:1265-1274 (2002). [cited by applicant]
Garcel et al. “Phenotypic and genetic diversity of the traditional Lister smallpox vaccine,” Vaccine, 27:708-17 (2009). [cited by applicant]
Garcia-Castro et al., “Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study,” Cancer Gene Therapy, 17(7): 476-83 (2010). [cited by applicant]
GenBank Accession No. AY313847.1, “Vaccinia virus strain Acambis clone 2000, complete genome” (2010) (82 pages). [cited by applicant]
Greenberg et al., “ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine,”Expert Opinion on Investigational Drugs, 17:555-564 (2008). [cited by applicant]
Guo, et al., “Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses,” Biochimica et Biophysica Acta, 1785: 217-231 (2008). [cited by applicant]
Hammad et al., “Neural Stem Cell Delivery of a Chimeric Orthopoxvirus in Combination with PD-1 Antibody for the Treatment of Metastatic Ovarian Cancer in Mice,” Molecular Therapy, 27(4S1):127-128 (2019). [cited by applicant]
Imperiale, “Re-creation of Horsepox Virus,” mSphere, 3(2)e00079-18 (2018)(1 page). [cited by applicant]
Jefferson, et al., “The mechanisms of genetically modified vaccinia viruses for the treatment of cancer,” Critical Reviews in Oncology/Hematology, 95(3):407-416 (2015). [cited by applicant]
Kennedy et al., “T-Cell epitope discovery for variola and vaccinia viruses,” Reviews in Medical Virology,17: 93-113 (2007). [cited by applicant]
Kim, et al., “Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions,” Viruses, 7(12):6200-6217 (2015). [cited by applicant]
Koblentz, “A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virux,” mSphere, 3(2)e00040-18 (2018)(10 pages). [cited by applicant]
Koblentz, “The De Novo Synthesis of Horsepox Virus: Implications for Biosecurity and Recommendations for Preventing the Reemergence of Smallpox,” Health Security, 15(5):620-628 (2017). [cited by applicant]
Komarova et al., “Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses,” Molecular Cancer Therapeutics, 5(30:755-766 (2006). [cited by applicant]
Kupferschmidt, “A paper showing how to make a smallpox cousin just got published. Critics wonder why,” downloaded from http://www.sciencemag.org/news/2018/01/paper-showing-how-make-smallpox-cousin-just-got-published-cri… [cited by applicant]
Kupferschmidt, “How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA,” Science Magazine (2017) (5 pages). [cited by applicant]
Kushner, “Synthetic Biology Could Bring a Pox on Us All,” Science, (18 pages) (2019). [cited by applicant]
Li et al., Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication, Virology Journal, 3:88; 9 pages (2006). [cited by applicant]
Li et al., “Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A,” Journal of General Virology, 94(Pt. 4):806-815 (2014). [cited by applicant]
Li et al., “On the origin of smallpox: correlating variola phylogenies with historical smallpox records,” PNAS, 104:15787-15792 (2007). [cited by applicant]
Loy, “An Account of Some Experiments on the Origin of the Cow-Pox,” Webster (1801) (29 Pages). [cited by applicant]
Mack et al., “A prospective study of serum antibody and protection against smallpox,”The American Journal of Tropical Medicine and Hygiene, 21: 214-218 (1972). [cited by applicant]
Marriott et al., “Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge,” Vaccine, 26: 581-588 (2008). [cited by applicant]
Medaglia, et al., “Genomic analysis, phenotype, and virulence of the historical Brazilian smallpox vaccine strain IOC: Implications for the origins and evolutionary relationships of vaccinia virus,” Journal of Virology,… [cited by applicant]
Merkel et al., “Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities,” PNAS, 107:18091-18096(2010). [cited by applicant]
Monath et al., “ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)—a second-generation smallpox vaccine for biological defense,” International Journal of Infectious Diseases, 8(Supp … [cited by applicant]
Morikawa et al., “An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection,” Journal of Virology, 79:11873-11891 (2005). [cited by applicant]
Murphy et al., “Adventitious Agents and Smallpox Vaccine in Strategic National Stockpile,” Emerging Infectious Diseases, 11(7):1086-1089 (2005). [cited by applicant]
Nalca et al., “ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile,” Drug Design, Development Therapy, 4:71-79 (2010). [cited by applicant]
Noyce et al., “Construction of an infectious horsepox virus vaccine from chemically synthesized DNA Fragments,” PLOS One, 13(1):e0188453 (2018) (16 pages). [cited by applicant]
Noyce, et al., “Synthetic horsepox viruses and the continuing debate about dual use research,” PLoS Pathogens, 14(10):e1007025 (2018) (5 pages). [cited by applicant]
Oldfield et al., “Genome-wide engineering of an infectious clone of herpes simplex virus type 1 using synthetic genomics assembly methods,” PNAS, 114(42):e8885-e8894 (2017). [cited by applicant]
Osborne et al., “Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3,” Vaccine, 25:8807-8832 (2007). [cited by applicant]
Paez et al., “Stability of vaccinia virus DNA during persistent infections: accumulation of left-end deletions and of tandem repeats at both ends of the viral genome and prevention by interferon,” Virology, 163(1):145-1… [cited by applicant]
Park et al., “Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer,” Molecular Therapy, 23(9):1532-2540 (2015). [cited by applicant]
Qin et al., “Evolution of and evolutionary relationships between extant vaccinia virus strains,” Journal of Virology, 89(3):1809-1824 (2015). [cited by applicant]
Qin et al., “Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine,” Journal of Virology, 85(24):13049-013060 (2011). [cited by applicant]
Ramírez, et al., “Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology,” Oncolytic Virotherapy, 4:149-155 (2015). [cited by applicant]
Sam et al., “Expression of poxvirus DNA in coinfected cells and marker rescue of thermosensitive mutants by subgenomic fragments of DNA,” Annales de 1Institut Paseur/Virologie, 132(2):135-150 (1981). [cited by applicant]
Sarkar et al., “The minimum protective level of antibodies in smallpox,” Bull World Health Organ, 52:307-311 (1975). [cited by applicant]
Scheiflinger et al., “Construction of chimeric vaccinia viruses by molecular cloning and packaging, ” PNAS, 89(21):9977-81 (1992). [cited by applicant]
Schrick et al., An Early American Smallpox Vaccine Based on Horsepox, New England Journal of Medicine, 377(15):1491-1492 (2017). [cited by applicant]
Shvalov et al., “Complete Genome Sequence of Vaccinia Virus Strain L-IVP,” Genome Announcements, 4(3):e00372-16 (2016). [cited by applicant]
Tcherepanov et al., “Genome Annotation Transfer Utility (GATU): rapid annotation of viral genomes using a closely related reference genome,” BMC Genomics, 7:150 (2006) (10 pages). [cited by applicant]
Tonix Pharmaceuticals Press Release “Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus f… [cited by applicant]
Tulman et al., “Genome of horsepox virus,” Journal of Virology, 80(18):9244-9258 (2006). [cited by applicant]
Walsh et al., “Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors,” Expert Review of Vaccines, 10:1221-1240 (2011). [cited by applicant]
Weltzin et al., “Clonal vaccinia virus grown in cell culture as a new smallpox vaccine,” Nature Medicine, 9(9):1125-1130 (2003). [cited by applicant]
WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting, Nov. 2-3, 2016, Geneva, Switzerland, World Health Organisation, ww.who.int/csr/resources/publications/smallpox/variola-research-novembe… [cited by applicant]
Yao et al., “Construction of recombinant vaccinia viruses using leporipoxvirus-catalyzed recombination and reactivation of orthopoxvirus DNA,” Methods in Molecular Biology, 269:51-64 (2004). [cited by applicant]
Yao et al., “High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells,” Journal of Virology, 77(13):7281-7290 (2003). [cited by applicant]
Zhang et al., “Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus,” Cancer Research, 67(20):10038-46 (2007). [cited by applicant]
Willer et al., “The complete genome sequence of shope (rabbit) fibroma virus,” Virology, 264(2):319-343 (1999). [cited by applicant]
Becker et al., “Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice,” PNAS, 105(50):19944-9 (2008). [cited by applicant]
Cello et al., “Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template,” Science, 297:1016-1018 (2002). [cited by applicant]
Tumpey et al., “Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus,” Science, 310:77-80 (2005). [cited by applicant]
Wimmer et al., “Synthetic viruses: a new opportunity to understand and prevent viral disease,” Nature Biotechnology, 27(12):1163-72 (2009). [cited by applicant]
Kettle et al., “Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode Mr 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model,” Virology, 206:136-147 (1995). [cited by applicant]